All Updates

All Updates

icon
Filter
Funding
Co-diagnostics secures USD 1.2 million from NIH
Precision Medicine
Jul 13, 2023
This week:
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Funding
OceanWell raises USD 11 million in Series A funding to build water farms
Conservation Tech
Yesterday
Product updates
H launches Runner H, an AI agent for business automation
Foundation Models
Yesterday
Partnerships
Capgemini partners with Mistral AI and Microsoft to expand GenAI solutions globally
Foundation Models
Yesterday
Funding
Product updates
Converge Bio launches biotech LLM platform with USD 5.5 million seed funding
Foundation Models
Yesterday
Partnerships
Snowflake partners with Anthropic to integrate Claude AI models into Cortex AI platform
Foundation Models
Yesterday
Product updates
DeepSeek releases AI reasoning model DeepSeek-R1
Foundation Models
Yesterday
Industry news
Partnerships
ICEYE partners with Lockheed Martin and Finnish firms to develop defense space technologies
Next-gen Satellites
Yesterday
Partnerships
Dematic installs AutoStore system at South West Healthcare logistics hub
Logistics Tech
Yesterday
Precision Medicine

Precision Medicine

Jul 13, 2023

Co-diagnostics secures USD 1.2 million from NIH

Funding

  • Molecular diagnostics company Co-Diagnostics, Inc. has received USD 1.2 million in funding from the National Institutes of Health (NIH) through the RADx Tech program. This brings the total funds raised by the company to USD 6.2 million.

  • The funds will be used to finalize the development of the company’s flu A/B, Covid-19, and RSV multiplex test and prepare for clinical trials on the Co-Dx PCR Home platform. The company also plans to submit the platform to the FDA and launch the Covid-19 test as its initial product.

  • Co-Diagnostics, Inc. is a molecular diagnostics company that develops, manufactures, and markets advanced diagnostic technologies. Its Co-Dx PCR Home platform utilizes nucleic acid detection and analysis to create tests for infectious diseases, including Covid-19. The company aims to make high-quality and affordable diagnostics more accessible globally. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.